person · Reporting owner

Hearne Michael S

Disclosed activity across 3 companies

Tapewire entity: 45594
SEC CIK: 0001759910

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aurinia Pharmaceuticals Inc.AUPH · Entity 4463	Chief Financial Officer	May 18, 2026	May 20, 2026
Odonate Therapeutics, Inc.ODT · Entity 132524	Chief Financial Officer	November 17, 2021	November 19, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aurinia Pharmaceuticals Inc.

Report date May 18, 2026 · Filed May 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	116,144	Reported balance After 2026-05-18 transaction · row 1 1 source row Row 1 · 2026-05-18 · Grant · Acquired 116,144 · Balance 116,144 F1: Each performance stock unit ("PSU") represents a contingent right to receive one common share of the Issuer. 46,820 PSUs vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. 69,324 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.28 · Expires 2036-05-18	Direct	70,230	Reported balance After 2026-05-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-18 · Grant · Acquired 70,230 · Balance 70,230 F2: 33% vest on the 1-year anniversary of the grant date, and the remaining 67% vest equally in monthly installments over the following 2 years.

Filing footnotes · ownership attribution and instrument terms

F1: Each performance stock unit ("PSU") represents a contingent right to receive one common share of the Issuer. 46,820 PSUs vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. 69,324 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date.

F2: 33% vest on the 1-year anniversary of the grant date, and the remaining 67% vest equally in monthly installments over the following 2 years.

Odonate Therapeutics, Inc.

Report date November 17, 2021 · Filed November 19, 2021

Jointly reported with TANG KEVIN, TANG CAPITAL PARTNERS LP, TANG CAPITAL MANAGEMENT LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy LP	12,767,435	Last balance in matching sequence After 2021-11-19 transaction · row 8 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 8 source rows Row 1 · 2021-11-17 · Sale · Disposed 468,849 · Balance 15,045,717 F1: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 2 · 2021-11-17 · Sale · Disposed 31,151 · Balance 15,014,566 F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 3 · 2021-11-17 · Sale · Disposed 500,000 · Balance 14,514,566 F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 4 · 2021-11-17 · Sale · Disposed 287,577 · Balance 14,226,989 F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 5 · 2021-11-18 · Sale · Disposed 212,423 · Balance 14,014,566 F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 6 · 2021-11-18 · Sale · Disposed 500,000 · Balance 13,514,566 F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 7 · 2021-11-18 · Sale · Disposed 381,842 · Balance 13,132,724 F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 8 · 2021-11-19 · Sale · Disposed 365,289 · Balance 12,767,435 F9: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.

Filing footnotes · ownership attribution and instrument terms

F1: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein.

F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.

F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005.

F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07.

F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33.

F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16.

F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99.

F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001.

F9: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

LA JOLLA PHARMACEUTICAL CO

Report date August 22, 2022 · Filed August 24, 2022

Section 16 reporting ended · disclosed 2022-08-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.63	Direct	Reported balance After 2022-08-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-08-22 · Disposition to issuer · Disposed 1,675 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46	Direct	Reported balance After 2022-08-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-08-22 · Disposition to issuer · Disposed 169 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09	Direct	Reported balance After 2022-08-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-08-22 · Disposition to issuer · Disposed 185 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27	Direct	Reported balance After 2022-08-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-08-22 · Disposition to issuer · Disposed 177 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.37	Direct	Reported balance After 2022-08-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-08-22 · Disposition to issuer · Disposed 173 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08	Direct	Reported balance After 2022-08-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-08-22 · Disposition to issuer · Disposed 185 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20	Direct	Reported balance After 2022-08-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-08-22 · Disposition to issuer · Disposed 236 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.19	Direct	Reported balance After 2022-08-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-08-22 · Disposition to issuer · Disposed 236 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Series C-1 (2) Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBY LP	Reported balance After 2022-08-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-08-22 · Other · Disposed 3,519.315 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-12 Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price. F3: The Shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time").

F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.

F3: The Shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP.

F4: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-12 Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 15, 2020 Filed Jul 17, 2020 16:04 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	17	$34.99	$594.83	Disclosure SEC source: 0001209191-20-042781 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,712 F1 · kind: These shares were acquired on 07/15/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:25 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	15	$0.00 Strike: $42.34	$0.00	Disclosure SEC source: 0001209191-20-040305 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15 Underlying: Common Stock · 15 shares Expires 2030-06-30 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:25 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	15	$35.99	$539.85	Disclosure SEC source: 0001209191-20-040305 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 F1 · kind: These shares were acquired on 06/30/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
June 15, 2020 Filed Jun 17, 2020 16:27 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	17	$0.00 Strike: $40.25	$0.00	Disclosure SEC source: 0001209191-20-037267 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17 Underlying: Common Stock · 17 shares Expires 2030-06-15 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
June 15, 2020 Filed Jun 17, 2020 16:27 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	17	$34.21	$581.57	Disclosure SEC source: 0001209191-20-037267 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,680 F1 · kind: These shares were acquired on 06/15/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
June 04, 2020 Filed Jun 4, 2020 18:26 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	PurchaseCommon Stock	215,812	$4.94	$1,065,636.49	Disclosure SEC source: 0001209191-20-034535 · doc4.xml · nonDerivative · entry 3 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 8,695,474 F4 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $4.86 to $5.00. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document
June 03, 2020 Filed Jun 4, 2020 18:26 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	PurchaseCommon Stock	145,764	$4.90	$714,782.93	Disclosure SEC source: 0001209191-20-034535 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 8,479,662 F3 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $4.775 to $5.00. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document
June 02, 2020 Filed Jun 4, 2020 18:26 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	PurchaseCommon Stock	253,553	$4.88	$1,237,059.73	Disclosure SEC source: 0001209191-20-034535 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 8,333,898 F1 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $4.555 to $5.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 4 herein. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document
June 01, 2020 Filed Jun 3, 2020 16:05 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	GrantStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $4.55	$0.00	Disclosure SEC source: 0000920465-20-000086 · wf-form4_159121468942434.xml · derivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-06-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document
May 29, 2020 Filed Jun 2, 2020 16:04 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	40	$0.00 Strike: $32.67	$0.00	Disclosure SEC source: 0001209191-20-033460 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40 Underlying: Common Stock · 40 shares Expires 2030-05-29 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
May 29, 2020 Filed Jun 2, 2020 16:04 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	40	$27.77	$1,110.80	Disclosure SEC source: 0001209191-20-033460 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,663 F1 · kind: These shares were acquired on 05/29/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
May 15, 2020 Filed May 19, 2020 20:14 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	47	$0.00 Strike: $28.24	$0.00	Disclosure SEC source: 0001209191-20-030767 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47 Underlying: Common Stock · 47 shares Expires 2030-05-15 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
May 15, 2020 Filed May 19, 2020 20:14 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	47	$24.00	$1,128.00	Disclosure SEC source: 0001209191-20-030767 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,623 F1 · kind: These shares were acquired on 05/15/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
April 30, 2020 Filed May 4, 2020 16:03 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	47	$0.00 Strike: $28.15	$0.00	Disclosure SEC source: 0001209191-20-026745 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47 Underlying: Common Stock · 47 shares Expires 2030-04-30 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
April 30, 2020 Filed May 4, 2020 16:03 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	47	$23.93	$1,124.71	Disclosure SEC source: 0001209191-20-026745 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,576 F1 · kind: These shares were acquired on 04/30/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
April 15, 2020 Filed Apr 17, 2020 16:07 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	50	$0.00 Strike: $26.85	$0.00	Disclosure SEC source: 0001209191-20-024778 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50 Underlying: Common Stock · 50 shares Expires 2030-04-15 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
April 15, 2020 Filed Apr 17, 2020 16:07 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	50	$22.82	$1,141.00	Disclosure SEC source: 0001209191-20-024778 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,529 F1 · kind: These shares were acquired on 04/15/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
March 31, 2020 Filed Apr 2, 2020 16:13 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	24	$0.00 Strike: $27.61	$0.00	Disclosure SEC source: 0001209191-20-022527 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24 Underlying: Common Stock · 24 shares Expires 2030-03-31 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
March 31, 2020 Filed Apr 2, 2020 16:13 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	24	$23.47	$563.28	Disclosure SEC source: 0001209191-20-022527 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479 F1 · kind: These shares were acquired on 03/31/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
March 13, 2020 Filed Mar 17, 2020 16:17 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	29	$0.00 Strike: $23.05	$0.00	Disclosure SEC source: 0001209191-20-019571 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29 Underlying: Common Stock · 29 shares Expires 2030-03-13 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
March 13, 2020 Filed Mar 17, 2020 16:17 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	29	$19.59	$568.11	Disclosure SEC source: 0001209191-20-019571 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,455 F1 · kind: These shares were acquired on 03/13/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
February 28, 2020 Filed Mar 3, 2020 16:05 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	22	$0.00 Strike: $29.59	$0.00	Disclosure SEC source: 0001209191-20-015076 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22 Underlying: Common Stock · 22 shares Expires 2030-02-28 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
February 28, 2020 Filed Mar 3, 2020 16:05 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	22	$25.15	$553.30	Disclosure SEC source: 0001209191-20-015076 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,426 F1 · kind: These shares were acquired on 02/28/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
February 14, 2020 Filed Feb 19, 2020 16:12 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	21	$0.00 Strike: $31.45	$0.00	Disclosure SEC source: 0001209191-20-010499 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21 Underlying: Common Stock · 21 shares Expires 2030-02-14 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
February 14, 2020 Filed Feb 19, 2020 16:12 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	21	$26.73	$561.33	Disclosure SEC source: 0001209191-20-010499 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,404 F1 · kind: These shares were acquired on 02/14/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
January 31, 2020 Filed Feb 4, 2020 16:31 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	23	$0.00 Strike: $29.20	$0.00	Disclosure SEC source: 0001209191-20-006365 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23 Underlying: Common Stock · 23 shares Expires 2030-01-31 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
January 31, 2020 Filed Feb 4, 2020 16:31 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	23	$24.82	$570.86	Disclosure SEC source: 0001209191-20-006365 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,383 F1 · kind: These shares were acquired on 01/31/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
January 15, 2020 Filed Jan 17, 2020 16:02 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	24	$0.00 Strike: $27.23	$0.00	Disclosure SEC source: 0001209191-20-003921 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24 Underlying: Common Stock · 24 shares Expires 2030-01-15 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
January 15, 2020 Filed Jan 17, 2020 16:02 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	24	$23.15	$555.60	Disclosure SEC source: 0001209191-20-003921 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,360 F1 · kind: These shares were acquired on 01/15/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
December 31, 2019 Filed Jan 3, 2020 16:04 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	20	$0.00 Strike: $32.45	$0.00	Disclosure SEC source: 0001209191-20-000762 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20 Underlying: Common Stock · 20 shares Expires 2029-12-31 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
December 31, 2019 Filed Jan 3, 2020 16:04 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	20	$27.58	$551.60	Disclosure SEC source: 0001209191-20-000762 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,336 F1 · kind: These shares were acquired on 12/31/2019 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
December 13, 2019 Filed Dec 17, 2019 16:05 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	22	$0.00 Strike: $28.97	$0.00	Disclosure SEC source: 0001209191-19-060846 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22 Underlying: Common Stock · 22 shares Expires 2029-12-13 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
December 13, 2019 Filed Dec 17, 2019 16:05 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	22	$24.62	$541.64	Disclosure SEC source: 0001209191-19-060846 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,316 F1 · kind: These shares were acquired on 12/13/2019 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
December 10, 2019 Filed Dec 12, 2019 18:24 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	32,173	$0.00 Strike: $30.51	$0.00	Disclosure SEC source: 0001209191-19-060283 · doc4.xml · derivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,173 Underlying: Common Stock · 32,173 shares Expires 2029-12-10 F1 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
November 29, 2019 Filed Dec 3, 2019 16:02 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	19	$0.00 Strike: $34.38	$0.00	Disclosure SEC source: 0001209191-19-058680 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19 Underlying: Common Stock · 19 shares Expires 2029-11-29 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
November 29, 2019 Filed Dec 3, 2019 16:02 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	19	$29.22	$555.18	Disclosure SEC source: 0001209191-19-058680 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,294 F1 · kind: These shares were acquired on 11/29/2019 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
November 15, 2019 Filed Nov 19, 2019 18:04 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	19	$0.00 Strike: $33.10	$0.00	Disclosure SEC source: 0001209191-19-057305 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19 Underlying: Common Stock · 19 shares Expires 2029-11-15 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
November 15, 2019 Filed Nov 19, 2019 18:04 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	19	$28.14	$534.66	Disclosure SEC source: 0001209191-19-057305 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,275 F1 · kind: These shares were acquired on 11/15/2019 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
October 31, 2019 Filed Nov 4, 2019 16:11 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	21	$0.00 Strike: $31.76	$0.00	Disclosure SEC source: 0001209191-19-054872 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21 Underlying: Common Stock · 21 shares Expires 2029-10-31 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
October 31, 2019 Filed Nov 4, 2019 16:11 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	21	$27.00	$567.00	Disclosure SEC source: 0001209191-19-054872 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,256 F1 · kind: These shares were acquired on 10/31/2019 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
October 15, 2019 Filed Oct 17, 2019 17:46 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	22	$0.00 Strike: $28.50	$0.00	Disclosure SEC source: 0001209191-19-053461 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22 Underlying: Common Stock · 22 shares Expires 2029-10-15 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
October 15, 2019 Filed Oct 17, 2019 17:46 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	22	$24.23	$533.06	Disclosure SEC source: 0001209191-19-053461 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,235 F1 · kind: These shares were acquired on 10/15/2019 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
September 30, 2019 Filed Oct 2, 2019 16:02 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	25	$0.00 Strike: $26.03	$0.00	Disclosure SEC source: 0001209191-19-051592 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25 Underlying: Common Stock · 25 shares Expires 2029-09-30 F3 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
September 30, 2019 Filed Oct 2, 2019 16:02 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	25	$22.13	$553.25	Disclosure SEC source: 0001209191-19-051592 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,213 F1 · kind: These shares were acquired on 09/30/2019 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
September 13, 2019 Filed Sep 17, 2019 19:24 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	23	$0.00 Strike: $28.36	$0.00	Disclosure SEC source: 0001209191-19-049949 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23 Underlying: Common Stock · 23 shares Expires 2029-09-13 F3 · derivative.exercise_date: The stock options vest as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
September 13, 2019 Filed Sep 17, 2019 19:24 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	23	$24.11	$554.53	Disclosure SEC source: 0001209191-19-049949 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,188 F1 · kind: These shares were acquired on 09/13/2019 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
August 30, 2019 Filed Sep 4, 2019 16:18 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	21	$0.00 Strike: $30.81	$0.00	Disclosure SEC source: 0001209191-19-048184 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21 Underlying: Common Stock · 21 shares Expires 2029-08-30 F3 · derivative.exercise_date: The stock options vest as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
August 30, 2019 Filed Sep 4, 2019 16:18 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	21	$26.19	$549.99	Disclosure SEC source: 0001209191-19-048184 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,165 F1 · kind: These shares were acquired on 08/30/2019 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
August 15, 2019 Filed Aug 19, 2019 16:12 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantEmployee Stock Option (Right to Buy) · Derivative	19	$0.00 Strike: $33.44	$0.00	Disclosure SEC source: 0001209191-19-046530 · doc4.xml · derivative · entry 3 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19 Underlying: Common Stock · 19 shares Expires 2029-08-15 F3 · derivative.exercise_date: The stock options vest as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
August 15, 2019 Filed Aug 19, 2019 16:12 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantCommon Stock	19	$28.42	$539.98	Disclosure SEC source: 0001209191-19-046530 · doc4.xml · nonDerivative · entry 1 Hearne Michael S · CIK 0001759910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,144 F1 · kind: These shares were acquired on 08/15/2019 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.